Skip to main content
Premium Trial:

Request an Annual Quote

Sequoia Genetics Teams with Russian Academy on NGS-based Neonatal Dx

NEW YORK (GenomeWeb News) – Sequoia Genetics today said that it has partnered with the Research Centre of Medical Genetics of the Russian Academy of Medical Sciences to develop next-generation sequencing-based neonatal diagnostics.

The goal of the alliance is to develop a molecular diagnostic test for three inherited diseases that are included in obligatory newborn screening programs in Russia. Sequoia said that researchers involved in the project are developing a high-throughput assay that will detect all clinically relevant mutations in genes associated with cystic fibrosis, phenylketonuria, and galactosemia.

Alexander Pavlov, CEO of Sequoia Genetics, said that the firm will use the assay to carry out testing of clinical samples provided by the RCMG. Specialists from Sequoia and the RCMG will jointly interpret the results to determine clinical efficacy of the assay, he said.

Sequoia is a member of the Saint Petersburg, Russia-based Alkor Bio group of companies.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.